3d • General discussion
⚖️ Semaglutide Patent Battle – A Quick Breakdown
The Core Dispute
- U.S. Patent No. 8,129,343 (expires 2030s) covers semaglutide's molecular structure
- Feb 2026: Novo Nordisk sued Hims & Hers over compounded semaglutide infringement
- First patent-infringement lawsuit between brand manufacturer & compounding pharmacy
International Challenge
- Dec 2025: Delhi High Court refused injunction against Dr. Reddy's
- Court found patent "prima facie vulnerable"
- Generic oral semaglutide launched in India (April 2026) → 40% volume increase
Patent Expiration
- Primary U.S. patents expire early 2030s
- No FDA-approved generic yet
- Generic launch typically 6–12 months post-expiration
The Legal Gray Zone
- Compounding exemptions don't automatically shield from patent claims
- Two separate questions: FDA rules vs. patent rights
Implications for Researchers
- Compounded products may be subject to patent infringement
- Access barriers until generics arrive
- Research-grade peptides require transparent sourcing
⚠️ Research only. Not for human consumption.
0
0 comments
⚖️ Semaglutide Patent Battle – A Quick Breakdown
powered by
skool.com/biohacking-and-longevity-group-3757
All-in-one peptide education community. 🧪
Dosing guides, storage protocols, stacking frameworks, vendor intel, GLP-1 research, and expert support.🧬
Suggested communities
Powered by